Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1969 1
1974 4
1975 1
1976 3
1977 2
1978 2
1979 1
1980 2
1981 3
1982 5
1983 11
1984 8
1985 3
1986 9
1987 9
1988 9
1989 9
1990 10
1991 12
1992 11
1993 6
1994 10
1995 3
1996 3
1997 9
1998 1
1999 1
2000 3
2001 2
2002 3
2003 8
2004 9
2005 8
2006 9
2007 16
2008 15
2009 16
2010 18
2011 20
2012 19
2013 21
2014 22
2015 23
2016 22
2017 23
2018 12
2019 14
2020 18
2021 15
2022 12
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

431 results

Results by year

Filters applied: . Clear all
Page 1
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F; REACH3 Investigators. Zeiser R, et al. N Engl J Med. 2021 Jul 15;385(3):228-238. doi: 10.1056/NEJMoa2033122. N Engl J Med. 2021. PMID: 34260836 Clinical Trial.
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Socié G; REACH2 Trial Group. Zeiser R, et al. N Engl J Med. 2020 May 7;382(19):1800-1810. doi: 10.1056/NEJMoa1917635. Epub 2020 Apr 22. N Engl J Med. 2020. PMID: 32320566 Clinical Trial.
Design of Wall-Destructive but Membrane-Compatible Solvents.
Kuroda K, Satria H, Miyamura K, Tsuge Y, Ninomiya K, Takahashi K. Kuroda K, et al. Among authors: miyamura k. J Am Chem Soc. 2017 Nov 15;139(45):16052-16055. doi: 10.1021/jacs.7b08914. Epub 2017 Oct 10. J Am Chem Soc. 2017. PMID: 28985068
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial.
Teshima T, Onishi Y, Kato K, Taniguchi S, Miyamura K, Fukushima K, Kato J, Ishikawa T, Doki N, Nakamae H, Maeda Y, Inamoto Y, Okada M, Maki A, Shimada F, Tajima T, Wroclawska M, Zeiser R, Onizuka M. Teshima T, et al. Among authors: miyamura k. Int J Hematol. 2024 Jul;120(1):106-116. doi: 10.1007/s12185-024-03772-6. Epub 2024 May 25. Int J Hematol. 2024. PMID: 38796666 Free PMC article. Clinical Trial.
Improved Long-Term Net Survival after Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies over Two Decades.
Ohbiki M, Ito Y, Inamoto Y, Miyamura K, Uchida N, Fukuda T, Fujiwara H, Nishida T, Hayashi M, Tanaka M, Kawakita T, Ikegame K, Katayama Y, Ara T, Ichinohe T, Kiyoi H, Matsuo K, Atsuta Y. Ohbiki M, et al. Among authors: miyamura k. Transplant Cell Ther. 2023 Dec;29(12):768.e1-768.e10. doi: 10.1016/j.jtct.2023.09.010. Epub 2023 Sep 21. Transplant Cell Ther. 2023. PMID: 37739224
[Increasing options of stem cell sources].
Miyamura K. Miyamura K. Rinsho Ketsueki. 2013 Feb;54(2):145-55. Rinsho Ketsueki. 2013. PMID: 23470821 Review. Japanese. No abstract available.
431 results